AzTrials
AzTrials

Post Operative AnalgesiaPhase 4NCT06783764

Comparative Study Between Combined Modified Pectoral Nerve Block (PECSΙΙ) and Transversus Thoracic Plane Block Versus Erector Spinae Plane Block for Post-operative Analgesia Following Breast Surgeries, (randomized Clinical Trial Study)

A Phase 4 study testing PECS II block and transverse thoracic plane block, Erector Spinae Plane Block and bupivacaine 0.25 % injection in people with Post Operative Analgesia and Post Operative Pain, run by Ain Shams University at 1 site in Egypt.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The aim of this study is to compare the analgesic effect and safety of Modified Pectoral Nerve Block and Transverse thoracic plane block versus Erector Supine plane Block in cases undergoing modified radical mastectomy (MRM). Read more about this study

Who is it for?
Ages 25 to 65 years, women only
Conditions the study is for
Post Operative Analgesia, Post Operative Pain
What is being tested?
PECS II block and transverse thoracic plane block, Erector Spinae Plane Block and bupivacaine 0.25 % injection
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteEgypt
Study dates
1 May 2024to 5 Mar 2025
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 65 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 25-65 years.
  • BMI 18-35.
  • American Society of Anesthesiologists(ASA) Physical Status Class-I, II and III Scheduled for breast surgery

Who cannot join

  • - Refusal to give written informed consent.
  • History of allergy to the medications used in the study.
  • Contraindications to regional anesthesia (including coagulopathy -INR>1.6, PLT<50 × 10^3/cmm- and local infection).
  • Psychiatric disorder that leading to inability to cooperate, speak or read.
  • BMI more than 35.
  • Patients on medications for chronic pain.
  • Previous anterior chest wall surgery.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Ain Shams University

    Cairo, Abbasia

Other trials in Egypt

About this study

The aim of this study is to compare the analgesic effect and safety of Modified Pectoral Nerve Block and Transverse thoracic plane block versus Erector Supine plane Block in cases undergoing modified radical mastectomy (MRM).

Read the detailed description

The aim of this study is to compare the analgesic effect and safety of Modified Pectoral Nerve Block and Transverse thoracic plane block versus Erector Supine plane Block in cases undergoing modified radical mastectomy (MRM).

Primary outcome: The Nalbuphine consumption in the first 24 hours post-operative.

Secondary outcome Severity of pain will be recorded through the Visual Analogue Scale (VAS) on arrival to PACU (T0) then at 4, 8, 12, 16, 20, and 24hr postoperatively.

  • Study Population: Adult female patients,aged 25-65 years undergoing modified radical mastectomy will be assigned into two equal groups using simple randomization computer generated method.
  • Group A: will receive a combination of PECS II block and TTPB (injection of 10 ml 0.25% bupivacaine between pectoralis major and minor muscles and 10 ml between the pectoralis minor and serratus anterior muscles) at the third or the fourth rib, then 10 ml between the internal inter-costal muscles and the transversus thoracic muscle (Abedalmohsen, 2023).
  • Group B: ESPB (30 ml of 0.25% bupivacaine injected deep to the erector spinae muscle at the transverse process of the fifth thoracic vertebrae). (Abedalmohsen, 2023).
  • There's no control group.

Inclusion Criteria:

  • Age 25-65 years.
  • BMI 18-35.
  • American Society of Anesthesiologists(ASA) Physical Status Class-I, II and III.
  • Scheduled for breastsurgery.

Exclusion Criteria:

  • Refusal to give written informed consent.
  • History of allergy to the medications used in the study.
  • Contraindications to regional anesthesia (including coagulopathy -INR>1.6, PLT<50 × 10^3/cmm- and local infection).
  • Psychiatric disorder that leading to inability to cooperate, speak or read.
  • BMI more than 35.
  • Patients on medications for chronic pain.
  • Previous anterior chest wall surgery.

Sampling Method:

Simple randomization computer guaranteed. Patients will be divided into 2 groups via sealed envelopes randomly distributed to them and will be enrolled into group A, group B.

-Sample Size: After reviewing previous study results (Abedalmohsen and Bakri, 2024) showing that among patients underwent modified radical mastectomy, the morphine consumption (mg) in postoperative follow up period was lower in patients received erector spinae plane block than in patients received erector spinae plane block (0.93 + 0.63 versus 2.13 + 0.42 respectively); a sample size of at least 40 adult female patients undergoing modified radical mastectomy divided randomly into 2 groups (20 patients in each group) will achieve 100% power, at significance level 0.05, by using Power Analysis and Sample Size Software (PASS 15) (Version 15.0.10) for sample size calculation.

Preoperative settings:

After history taking and clinical examination, routine preoperative investigations will be done to all patients including:

  • Laboratory investigations as (complete blood picture, bleeding time, prothrombin time, partial thromboplastin time, Kidney function, Liver functions and viral markers)
  • Imaging investigations as plain chest x-ray.
  • Vas score will be explained to details to the patient and full understanding will be confirmed

Intraoperative settings:

  • General anaesthesia will be carried out as per our institution protocol
  • Intraoperative monitoring of ECG, HR, NIBP, SpO2 and capnography will be continued throughout the operation (Bakeer et al., 2020).

After completion of surgery and before extubation:

Group A:

All blocks will be performed by an experienced anesthetist.

US-guided PECSII block will be done on the same side of surgery with the patient lying in the supine position and the ipsilateral arm will be abducted and externally rotated, and the elbow flexed 90°.(Sonosite turbo M, Bothell, Washington, USA) and linear ultrasound probe(2.5-7.5MHZ) Transduser will be put in the ipsilateral para median sagittal plane in order to identify the coracoid process. Then the transducer is rotated slightly to allow an in-plane needle trajectory from the proximal and medial side toward the lateral side (ie, the caudal border of the transducer is moved laterally, while the proximal border remains unchanged). This rotation helps image the pectoral branch of the thoracoacromial artery.

After identification of the Pectoralis major muscle, Pectoralis minor muscle, Serratus anterior muscle and the planes in between, the 1st injection will be in the plane between the Pectoralis minor muscle and the serratus anterior muscle. The needle (disposable spinal needle, K-3 point type LUER-Lock HUB 22G) will be advanced in an in-plane technique. Two mL of normal saline will be injected to confirm the location, produce hydro-dissection, and improve needle visualization. Afterward, 20 mL of bupivacaine, 0.25%, will be injected. During the withdrawal of the needle a 2nd injection will be done in the plane between the Pectoralis major muscle and the Pectoralis minor muscle. 2ml of normal saline will be injected to produce hydro-dissection and confirm the location. 10ml of Bupivicaine 0.25% will be injected (Bakeer et al., 2020).The TTPB, 10 ml bupivacaine 0.25% was injected between the deep transversus thoracic and the superficial internal inter-costal muscles para-sternal between the third and fourth left ribs under US guidance (Abedalmohsen, 2023).

GroupB:

The ESP block will be performed positioning the patient in the lateral decubitus position with probe placement in cranio cephalad orientation by identifying the spinous process in the upper thoracic area and subsequently transverse process by moving the probe laterally as an oval hyperechoic sonographic structure. In total, 20 ml of 0.25% bupivacaine will be deposited between the erector spinae muscle and transverse process using a Sono Plex Stim cannula (21G X 100 mm, Pajunk, Germany) with the in plane technique after hydro dissection and negative aspiration. The patient will be turned supine after block placement 1gm of paracetamol, 30mg of ketorolac and 1mg Granitryl will be given to all patients. The patient will then be transferred to recovery room for follow up.(Bakeer et al., 2020).

Postoperative settings:

In the first postoperative 24 hours, VAS score will be assessed at 0, 2 ,4, 8, 12, 16 and 24 hours postoperatively.

A dose of 5 mg Naluphin will be given if VAS score exceeded 3, to maintain a score less than 3, not to exceed 20 mg per dose. IV boluses of naluphin will be given as a rescue analgesia to maintain VAS ≤ 3,

. Paracetamol 1 gm IV infusion will be given every 8 hours and ketorolac 30 mg every 12 hours postoperatively (Stormholt et al., 2021).

Being tested
PECS II block and transverse thoracic plane block, Erector Spinae Plane Block, bupivacaine 0.25 % injection
Medical subject headings
Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PECS II block and transverse thoracic plane blockProcedure or surgery

    will receive a combination of PECS II block and TTPB (injection of 10 ml 0.25% bupivacaine between pectoralis major and minor muscles and 10 ml between the pectoralis minor and serratus anterior muscles) at the third or the fourth rib, then 10 ml between the internal inter-costal muscles and the transversus thoracic muscle

  • Erector Spinae Plane BlockProcedure or surgery

    ESPB (30 ml of 0.25% bupivacaine injected deep to the erector spinae muscle at the transverse process of the fifth thoracic vertebrae)

  • bupivacaine 0.25 % injectionDrug

    injection of 10 ml 0.25% bupivacaine between pectoralis major and minor muscles and 10 ml between the pectoralis minor and serratus anterior muscles) at the third or the fourth rib, then 10 ml between the internal inter-costal muscles and the transversus thoracic muscle

  • bupivacaine 0.25 % injectionDrug

    30 ml of 0.25% bupivacaine injected deep to the erector spinae muscle at the transverse process of the fifth thoracic vertebrae

Study groups in NCT06783764
Study groupRoleWhat they receive
PECS II block and TTPB groupActive comparatorwill receive a combination of PECS II block and TTPB (injection of 10 ml 0.25% bupivacaine between pectoralis major and minor muscles and 10 ml between the pectoralis minor and serratus anterior muscles) at the third or the fourth rib, then 10 ml between the internal inter-costal muscles and the transversus thoracic muscle
Receives: Procedure: PECS II block and transverse thoracic plane block; Drug: bupivacaine 0.25 % injection
ESPB groupActive comparator: ESPB (30 ml of 0.25% bupivacaine injected deep to the erector spinae muscle at the transverse process of the fifth thoracic vertebrae)
Receives: Procedure: Erector Spinae Plane Block; Drug: bupivacaine 0.25 % injection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The Nalbuphine consumption

    The Nalbuphine consumption in the first 24 hours post-operative.

    Measured: The first 24 hours post-operative.

Secondary outcomes (1)
  1. severity of pain post operative

    Severity of pain will be recorded through the Visual Analogue Scale (VAS) on arrival to PACU (T0) then at 4, 8, 12, 16, 20, and 24hr postoperatively

    Measured: The first 24 hours post-operative.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Jan 2025
  2. Study start1 May 2024
  3. Primary completion28 Feb 2025 (estimated)
  4. Study completion5 Mar 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06783764
Sponsor's protocol ID
FMASU MS560/2024
Status last verified
Jan 2025
First submitted
15 Jan 2025
Last updated
20 Jan 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing PECS II block and transverse thoracic plane block, Erector Spinae Plane Block and bupivacaine 0.25 % injection in people with Post Operative Analgesia and Post Operative Pain, run by Ain Shams University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 20 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The Nalbuphine consumption (time frame: The first 24 hours post-operative.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2025; AzTrials last refreshed its copy on 27 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in